Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U7 small nuclear 23 pseudogene (RNU7-23P) is classified as a pseudogene, meaning it represents a genomic sequence similar to a functional gene but is widely considered non-functional due to mutations or lack of expression. RNU7-23P originates from the U7 small nuclear RNA gene family whose functional snRNA (U7) participates in histone pre-mRNA 3' end processing, a critical step for the synthesis and regulation of histone proteins during the cell cycle[1][3][5]. However, as a pseudogene, RNU7-23P is not known to produce active RNA or protein, nor is it implicated in disease, drug interactions, or considered a therapeutic target. Its designation is mainly as a non-coding genomic relic, distinct from functional members such as RNU7-1, which have established roles in RNA maturation and disease association[2][4][5]. The inclusion of "pseudogene" in the name indicates it is not a functional molecular target and should not be used in place of the functional U7 snRNA or the genuine U7 snRNP complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 23 pseudogene (RNU7-23P).